Eli Lilly has purchased an integrated suite of cellular screening technology and licences to help in the identification of potential therapeutics in its drug discovery programme
Amersham reports that Eli Lilly has purchased an integrated suite of cellular screening technology and licences to help in the identification of potential therapeutics in its drug discovery programme.
In addition to the purchase of an In Cell analyser 3000 high-throughput sub-cellular imaging system, Lilly has signed an agreement with Amersham for rights to Aequorea Victoria green fluorescent protein (GFP).
Furthermore, Lilly has secured rights to operate under BioImage's Redistribution patent portfolio for monitoring intracellular signalling pathways, including protein translocation.
Utilising the advanced imaging quality and speed of the In Cell 3000 system in conjunction with the Aequorea Victoria GFP and Redistribution helps speed cellular screening capability and, ultimately, aid the discovery of new pharmaceuticals by examining disease-related targets in an informative biological context.
"We are delighted to be working with Lilly in this area," said Mike Evans, vice president marketing and strategy, discovery systems at Amersham Biosciences, "Lilly's decision to utilise GFP and Redistribution technology together with the In Cell 3000 reflects the trend in the pharmaceutical industry towards generating biological information earlier in the drug development process to speed up the time to market." "I am pleased that Lilly has chosen Redistribution to enhance its drug discovery program," said Patrik Dahlen, CEO of BioImage.
"We are proud to have contributed with the Redistribution technology and look forward to its further utilisation in drug discovery."
